Cancer Market Research Reports & Industry Analysis

Cancer is a package of diseases marked by uncurbed growth and proliferation of anomalous cells. The illness is generally assumed to be the fruit of the impact of assorted outside factors and inner forces, such as tobacco smoking, radiation exposure, chemicals’ influences, infectious agents, inherited gene mutations, hormonal disorders, immune system conditions and mutations of other origins, among others.

Thus far, the Cancer Market has already seen noticeable progress in early-stage tumor detection and cure globally. The market for Cancer diagnostics is close to explosive growth, promising to reach approximately EUR 4 billion in value by end-2015. Further, technology discoveries will continue to afford many chances of demystifying the genetic components of the sickness, identifying specific tumor types, and observing biological reaction to cancer treatments. However, the bulk of presently available therapies do not fully protect against some unwelcomed side-effects.

The research reports in this Catalogue present global, regional and nation-level analyses of the Cancer Market development trends over different time spans. The research reports identify major bizopps emerging in the Cancer Market; examine versatile Cancer diagnostic test technologies along with their applications, besides looking into other Cancer Market issues. The research reports also profile the top players and would-be entrants, as well as offer test volume and sales projections.

Found 1438 publications
Cancer Nanomedicine Market & Pipeline Insight 2015 US$ 2,000.00

... cancer therapy can be achieved. “Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight Nanomedicine for Cancer Therapies Cancer Nanoparticles Drug Delivery Systems Classification Mechanism of Cancer Nanomedicine Therapy Cancer Nanomedicine Clinical Pipeline Overview Cancer Nanomedicine ...

Feb, 2015 220 pages
Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H1 2015 US$ 2,000.00

... Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H1 2015’, provides an overview of the Paraganglioma (Glomus Jugulare Tumor)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor ...

Jan, 2015 54 pages
Leiomyosarcoma - Pipeline Review, H1 2015 US$ 2,000.00

... Leiomyosarcoma - Pipeline Review, H1 2015’, provides an overview of the Leiomyosarcoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment ...

Jan, 2015 86 pages
Follicular Thyroid Cancer - Pipeline Review, H1 2015 US$ 2,000.00

... Thyroid Cancer - Pipeline Review, H1 2015’, provides an overview of the Follicular Thyroid Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment ...

Jan, 2015 73 pages
Biliary Cirrhosis - Pipeline Review, H1 2015 US$ 2,000.00

Biliary Cirrhosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Biliary Cirrhosis - Pipeline Review, H1 2015’, provides an overview of the Biliary Cirrhosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis ...

Jan, 2015 75 pages
Global Skin Cancer Vaccine Market & Pipeline Insight 2015 US$ 1,500.00

... Skin Cancer Vaccine Global Skin Cancer Vaccine Market Analysis Global Skin Cancer Vaccine Pipeline by Company & Phase Global Skin Cancer Vaccine Pipeline: 47 Vaccines Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines Marketed Skin Cancer Vaccines ...

Feb, 2015 179 pages
Global Lung Cancer Vaccine Market & Pipeline Insight 2015 US$ 1,200.00

... Lung Cancer Vaccine Global Lung Cancer Vaccine Market Analysis Global Lung Cancer Vaccine Pipeline by Company & Phase Global Lung Cancer Vaccine Pipeline: 29 Vaccines Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C & Vaxira) Personalized Cancer ...

Feb, 2015 120 pages
2015 US Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 850.00

This report provides an overview of the US cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 40 pages and 7 tables

Jan, 2015 40 pages
2015 UK Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 450.00

This report provides an overview of the U.K. cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 16 pages and 4 tables

Jan, 2015 16 pages
2015 Spain Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares US$ 750.00

This report provides an overview of the Spanish cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 16 pages and 7 tables

Jan, 2015 16 pages
2015 Japan Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 750.00

This report provides an overview of the Japanese cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 23 pages and 6 tables

Jan, 2015 23 pages
2015 Italy Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 650.00

This report provides an overview of the Italian cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 18 pages and 5 tables

Jan, 2015 18 pages
2015 Global Cancer Diagnostic Market: Facilities, Test Volumes, and Sales Forecasts by Country US$ 2,450.00

This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country. Contains ...

Jan, 2015 11 pages
2015 Germany Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 750.00

This report provides an overview of the German cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 25 pages and 7 tables

Jan, 2015 25 pages
2015 France Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test US$ 750.00

This report provides an overview of the French cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 25 pages and 7 tables

Jan, 2015 25 pages
2015 Emerging Point-of-Care Testing Markets: Cancer Clinics, Ambulatory Centers, Surgery Centers, Nursing Homes, Birth Centers US$ 12,500.00

... POC diagnostic technologies and products, by test. Competitive Assessments - Assessments of major suppliers and emerging market entrants, including their sales, product ... for new POC instruments and reagent systems with potentially significant market appeal during the next ten years.- Design criteria for ...

Jan, 2015 1007 pages
2015 Analysis of Emerging Cancer Diagnostic Tests, and Strategic Profile of Leading Suppliers US$ 3,500.00

... Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.The report includes an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing ...

Jan, 2015 286 pages
2015 Analysis of Cancer Diagnostic Technologies, and Strategic Profiles of Leading Suppliers US$ 3,500.00

... assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, ...

Jan, 2015 185 pages
2015 Analysis of Cancer Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers US$ 3,500.00

This 119-page report reviews current instrumentation technologies, and compares features of major automated and semiautomated analyzers used for cancer diagnostic testing. The report also presents strategic assessments of current and emerging suppliers of ...

Jan, 2015 119 pages
Small Molecule Cancer Drug Clinical Pipeline Insight US$ 2,400.00

... the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers. Development of small molecule cancer drug generally ... Insight” Report Findings: Role of Small Molecule Drug in Cancer Treatment Mechanism of Small Molecule Cancer Drug Small Molecule Cancer Drugs Market Dynamics ...

Jan, 2015 1650 pages
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease US$ 3,000.00

... the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two ... / IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma – JP, approved). While novel targets address unmet need ...

Jan, 2015 82 pages
2015 World Cancer Diagnostics Market Key Players: Strategic Assessments of Major Suppliers and Emerging Market Entrants US$ 2,500.00

This report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 80 pages

Jan, 2015 80 pages
2015 Emerging Cancer Diagnostic Tests and Companies Developing New Technologies US$ 2,850.00

... Factors, Lymphokines, Immunohistochemical Stains and others. The report presents an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing or ...

Jan, 2015 260 pages
2015 Global Cancer Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country US$ 2,450.00

This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country. Contains ...

Jan, 2015 11 pages
2015 US Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 9,800.00

'2015 US Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of ...

Jan, 2015 620 pages
2015 UK Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 6,800.00

'2015 UK Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of ...

Jan, 2015 565 pages
2015 Spanish Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 6,800.00

'2015 Spanish Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Spanish cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

Jan, 2015 565 pages
2015 Japanese Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 7,600.00

'2015 Japanese Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Japanese cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

Jan, 2015 590 pages
2015 Italian Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 6,800.00

2015 Italian Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Italian cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

Jan, 2015 570 pages
2015 German Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 6,800.00

'2015 German Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the German cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

Jan, 2015 585 pages
2015 French Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies US$ 6,800.00

'2015 French Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

Jan, 2015 585 pages
2015 Global Cancer Diagnostics Market: Toward a New Future for Tumor Markers R&D Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Country... US$ 34,750.00

... -tailored to your specific information needs and budget. “2015 Global Cancer Diagnostics Market: Toward a New Future for Tumor Markers R&D Oncogenes, ... Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and ...

Jan, 2015 1200 pages
2015 European Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK US$ 19,700.00

... during the next five years. The report examines trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging ... basis of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field ...

Jan, 2015 820 pages
Gene Therapy Oncology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape US$ 3,500.00

... presentation view. Report facts DelveInsight Gene Therapy Oncology Report: “Gene Therapy Oncology Insight: Pipeline Assessment, Market Trend, Technology and ... and their Funding availabilities. Identifying the upcoming leaders in the gene therapy market in the coming years. Getting a first mover advantage ...

Jan, 2015 190 pages
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 US$ 1,500.00

... body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body ... ” Report Highlights: Introduction to Prostate Cancer Vaccine Mechanism of Prostate Cancer Vaccine Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country ...

Jan, 2015 155 pages
Global Non Small Cell Lung Cancer Market & Pipeline Insight US$ 2,400.00

... rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these ... before providing medical care to NSCLC patients. “Global Non Small Cell Lung Cancer Market & Pipeline Insight” Report Highlights: NSCLC Therapy ...

Jan, 2015 750 pages
Dendritic Cell Cancer Vaccine Market & Clinical Insight US$ 1,800.00

... and elimination from the body. In 1868, Paul Langerhans discovered dendritic cells and thought that they are part of nervous system ... & Clinical Insight” Report Highlights: Introduction & Mechanism of Dendritic Cell Cancer Vaccines Dendritic Cell Vaccine Market Overview Market Dynamics (Drivers, Challenges ...

Jan, 2015 190 pages
Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... Erbitux and Vectibix are not recommended. In 2012, Sanofi/Regeneron’s Zaltrap (ziv-aflibercept) was approved by the FDA in combination with FOLFIRI ...

Nov, 2014 57 pages
Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... setting after progression on a 5-FU regimen. In April 2014, the EU label for Vectibix was updated to specify RAS wild-type disease rather than ...

Nov, 2014 58 pages
TS-1 (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... its new PharmaPoint Drug Evaluation report, “TS-1 (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause ... is also approved for other indications, including NSCLC and breast cancer (Shirasaka, 2008). TS-1 is not approved for the treatment of CRC in the ...

Nov, 2014 56 pages
Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... -type, Erbitux and Vectibix (FDA, press release, September 27, 2012). Stivarga was approved under FDA priority review, allowing approval within ...

Nov, 2014 56 pages
PharmaPoint: Colorectal Cancer - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... 2023 SUMMARY GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - US Drug Forecast and Market Analysis to 2023”. ... patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report ...

Nov, 2014 156 pages
PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... SUMMARY GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis ... of key events as well the drivers and restraints affecting the Japan CRC market. REASONS TO BUY Understand and capitalize by identifying products ...

Nov, 2014 153 pages
PharmaPoint: Colorectal Cancer - Current and Future Players US$ 2,995.00

... Future Players SUMMARY GlobalData has released its pharma report, “PharmaPoint: Colorectal Cancer - Current and Future Players”. The report is a vital source ... date information with in-depth analysis on the companies in the rapidly growing Colorectal Cancer Market. The report identifies and analyses the key ...

Nov, 2014 59 pages
PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis to 2023 US$ 4,995.00

... SUMMARY GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - China Drug Forecast and Market Analysis ... of key events as well the drivers and restraints affecting the China CRC market. REASONS TO BUY Understand and capitalize by identifying products ...

Nov, 2014 135 pages
PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

... SUMMARY GlobalData has released its new PharmaPoint Country Evaluation report, “PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis ... the government is likely to make similar moves in the future. As in the 5EU in general, cost effectiveness is a major priority for the Italian government ...

Nov, 2014 210 pages
Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023 ... Erbitux and Vectibix are not recommended. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally available anti-VEGF inhibitor, for the ...

Nov, 2014 70 pages
MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report ...

Nov, 2014 73 pages
Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... . This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent unresectable ...

Nov, 2014 57 pages
Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023 US$ 3,495.00

... 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Imprime PGG (Colorectal Cancer) - Forecast and Market Analysis to 2023”. ... enrollment of 795 patients, and these patients will be randomized (2:1) to either Imprime PGG and Erbitux or Erbitux alone. The trial has a primary ...

Nov, 2014 71 pages
1 2 3 4 5 >
Skip to top